These innovations of 2026 could have a particularly broad impact
Some innovations have potential beyond the bounds of a single industry. These honorees include a company that is combining AI and advanced genetic life science to better track disease pathology, and another developing models that could help avoid animal testing by simulating human organ functions. Algen Biotechnologies For blending genetics and AI to advance pathology One of the most promising…
In 2026, two groundbreaking technologies have the potential to revolutionize their respective industries, leading to far-reaching impacts beyond their initial applications. The first innovation comes from Algen Biotechnologies, a company that merges artificial intelligence with advanced genetic life science to improve disease pathology tracking.
Founded by a team that originated from Nobel Laureate Jennifer Doudna's lab, Algen Biotechnologies has developed a system called AlgenBrain. This system utilizes CRISPR and artificial intelligence to understand disease biology and accelerate next-generation therapeutic approaches. By mapping causal links between gene regulation and disease progression, Algen Biotechnologies aims to move beyond mere data analysis and generate practical solutions.
Recently, the company secured a significant partnership with pharmaceutical giant AstraZeneca, valued at $555 million. This collaboration allows Algen to tap into AstraZeneca's extensive immunology pipeline and leverage its expertise in AI-powered drug discovery.
The second notable innovation is a technology developed by Emulate, which focuses on creating human organ simulators to replace animal testing. Emulate's core technology, known as Organ-on-a-Chip, employs microfluidic devices containing human cells to replicate essential aspects of human organ functions. This cutting-edge approach provides more accurate data for modeling, particularly in predicting drug reactions, compared to traditional two-dimensional cell culture models.
Emulate's latest advancement, the Human Liver Chip, is nearing completion of the FDA's ISTAND qualification program. This accomplishment brings the company closer to potentially replacing animal testing in regulatory submissions for pharmaceuticals. By offering a more efficient and cost-effective alternative, Emulate's technology has the potential to transform the pharmaceutical industry and reduce the reliance on animal testing.
Both Algen Biotechnologies and Emulate are among the distinguished honorees recognized in Fast Company's 2026 Next Big Things in Tech awards.
Written by urgent.news from Fast Company's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
